Sue Hager
Advisory Partner
Bio:
Sue Hager is an Advisory Partner on the a16z Bio + Health team. She previously served as Chief Marketing Officer and Operating Partner for the same team, bringing deep operational and communications expertise to the firm's life sciences and healthcare portfolio.
Before joining Andreessen Horowitz, Sue was Chief Investor Relations and Communications Officer at Section 32, a venture capital firm focused on transformative healthcare and technology companies. Her career spans senior leadership roles at some of the most innovative organizations in life sciences, including EQRx (Nasdaq: EQRx) and Foundation Medicine (acquired by Roche), where she served as Chief Communications Officer and Head of Health Policy and Advocacy. During her six-year tenure at Foundation Medicine, she led the landmark effort to secure the first broad Medicare Coverage Decision for comprehensive genomic profiling in oncology — a milestone that significantly expanded patient access to precision medicine.
Earlier in her career, Sue held senior communications and corporate affairs roles at Bayer Healthcare, Myriant Corporation (acquired by PTT Global Chemical), Targanta Therapeutics (acquired by The Medicines Company), and Coley Pharmaceutical (acquired by Pfizer).
Sue holds a BS with honors in Biology and an MBA from Northeastern University in Boston. She serves on the Board of Directors of MassBio and the Emily Whitehead Foundation.